The START Center for Cancer Research (“START”) is set to have a significant presence at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Known for our commitment to the advancement of cancer research and treatment, we are excited to share that our team of Principal Investigators (PIs) will be involved in nearly 100 sessions, showcasing a broad range of topics essential to the development of early phase oncology trials.
Pioneering Research on New Therapies
Our presentations at ASCO 2024 will cover a diverse array of innovative therapeutic approaches in the treatment of solid tumors. These include first-in-human studies and early phase trials focusing on novel cytolytic antibodies, multi-targeted KRAS inhibitors, and emerging therapies designed to harness the immune system in new ways. Each study emphasizes the safety, efficacy, and pharmacokinetics of these promising new treatments, paving the way for more effective cancer care.
Breakthroughs in Drug Combinations and Targeted Treatments
The conference will also feature insights into cutting-edge combinations of therapeutic agents, such as estrogen receptor degraders paired with cyclin-dependent kinase inhibitors for breast cancer treatment, and PROTACs (proteolysis targeting chimeras) in various oncological applications. These presentations will highlight the potential of combining traditional therapies with innovative molecular targeted treatments to enhance patient outcomes.
Advancements in Molecular and Genetic Targeting
Our sessions will delve into the advancements in targeting specific molecular and genetic markers in oncology. This includes the development and trial results of drugs aimed at specific mutations and pathways known to contribute to cancer progression, offering hope for more personalized and effective treatment strategies.
Networking, Collaboration, and Education
ASCO 2024 is not merely a platform for presenting our research; it also serves as a crucial networking hub. Our PIs are eager to collaborate with global experts to foster advancements that can quickly be translated into clinical settings. Furthermore, we are dedicated to the education and mentoring of the next generation of oncologists through detailed discussions, workshops, and mentorship sessions.
Conclusion
START’s robust involvement in nearly 100 sessions at ASCO underscores our role as a leader in the research and development of early phase oncology trials. We are not only contributing our vast expertise but also actively shaping the future of oncology by exploring new frontiers in treatment and care. Our team’s efforts emphasize a deep commitment to enhancing patient outcomes and advancing the field of oncology.
We invite all ASCO participants to attend our sessions to gain insights into the innovative therapies and research strategies that will define the future of oncology. START is proud to lead these conversations, continuing our mission to push the boundaries of what is possible in cancer research.
To learn more about our presence at ASCO and to schedule a meeting with us, click here.
